Company logo

PRTG - Portage Biotech Inc.

NASDAQ -> Healthcare -> Biotechnology
Tortola, British Virgin Islands
Type: Equity

PRTG price evolution
PRTG
(in millions $) 30 Oct 2024 31 Jan 2024 30 Oct 2023 30 Jul 2023
Current assets
Cash
Short term investments
Net receivables $0.16 $0.59 $0.81
Inventory
Total current assets $7.52 $6.27 $10.89
Long term investments
Property, plant & equipment $0.26 $0.28 $0.29
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $49.03 $92.4 $98.37
Current liabilities
Accounts payable $2.66 $3.09 $2.59
Deferred revenue
Short long term debt
Total current liabilities $2.71 $3.14 $2.64
Long term debt $0.23 $0.24 $0.25
Total noncurrent liabilities
Total debt
Total liabilities $17.04 $24.74 $25.06
Shareholders' equity
Retained earnings -$186.61 -$147.98 -$143.56
Other shareholder equity -$0.88 -$3.86 -$2.56
Total shareholder equity
(in millions $) 1 May 2023 1 May 2022 30 Apr 2021 30 Apr 2020
Current assets
Cash $2.77 $3.15
Short term investments
Net receivables $0.8 $0.35 $0.68 $0.6
Inventory
Total current assets $13.68 $24.83 $4.95 $3.79
Long term investments
Property, plant & equipment $117.39
Goodwill & intangible assets
Total noncurrent assets $169.91 $169.38
Total investments
Total assets $99.13 $194.66 $174.86 $173.17
Current liabilities
Accounts payable $0.27 $0.19 $1.94 $1.27
Deferred revenue
Short long term debt
Total current liabilities $1.86 $0.78 $3.21 $2.57
Long term debt $3.4
Total noncurrent liabilities $24.05 $24.96
Total debt
Total liabilities $23.08 $73.46 $27.26 $27.53
Shareholders' equity
Retained earnings -$138.41 -$38.08 -$38.13 -$22.3
Other shareholder equity -$4.33 $0.96 $55.09 $50.13
Total shareholder equity
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $3.65 $4.09 $4.5
Operating income
Income from continuing operations
EBIT
Income tax expense -$2.55 -$2.55 $4.82
Interest expense -$0.01 -$0.09 $0.45
Net income
Net income -$0.95 -$1.73 -$7.32
Income (for common shares)
(in millions $) 1 May 2022 30 Apr 2021 30 Apr 2020 30 Apr 2019
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $15.59 $12.44 $5.98 $2.76
Operating income -$12.44 -$5.98 -$2.76
Income from continuing operations
EBIT
Income tax expense $4.35 $2.3 $0.74
Interest expense $0.77 $0.18 $0.56 $0.09
Net income
Net income -$16.87 -$15.83 -$5.33 -$2.63
Income (for common shares)
(in millions $) 30 Oct 2022 30 Jul 2022 1 May 2022 31 Jan 2022
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.62
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing -$3.01 $27.35 $27.35
Effect of exchange rate
Change in cash and equivalents -$8.31 -$2.18 $20.58 $22.83
(in millions $) 1 May 2022 30 Apr 2021 30 Apr 2020 30 Apr 2019
Net income -$17.19 -$7.25 -$3.59
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$4.28 -$3.71 -$0.86
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.86 -$0.45
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $27.35 $4.76 $0.7 -$0.05
Effect of exchange rate
Change in cash and equivalents $20.58 -$0.38 -$3.01 -$1.35
Fundamentals
Market cap N/A
Enterprise value N/A
Shares outstanding N/A
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio N/A
Quick ratio N/A